In nearly every medtech pitch deck, there is a slide that commands attention: the Total Addressable Market (TAM). The number is often in the billions. It signals scale, ambition, and upside.
But in our experience at MedTechGrowth, the TAM slide is also one of the most misunderstood elements of early-stage strategy.
Because TAM does not equal opportunity.
In healthcare, opportunity is not defined by theoretical demand. It is defined by constraints—clinical, economic, operational, and behavioral. Companies that confuse the two often build strategies around optimism rather than access.
Below are four questions we encourage teams to answer before relying on TAM-driven forecasts.
1. Where Do Procedures Actually Happen?
On paper, a procedure may be performed across thousands of sites. In practice, volume is often concentrated in a much smaller subset of institutions.
Understanding where meaningful procedure density exists—and which sites are commercially viable—dramatically narrows the true early market. Without this clarity, commercial plans risk being built around institutions that will never realistically convert.
2. Who Can Realistically Adopt First?
Adoption is never uniform.
Early adopters tend to share specific characteristics:
- Clinical champions willing to trial new technologies
- Institutions with innovation budgets
- Academic or high-complexity centers
- Defined patient populations aligned with your indication
The question is not “Who could use this?” but “Who will use this first?” Sequencing matters. A focused entry strategy almost always outperforms broad market targeting.
3. What Limits Access or Reimbursement?
Reimbursement pathways shape utilization as much as clinical value does.
If coding is unclear, coverage is inconsistent, or payment levels are misaligned with workflow burden, adoption slows—regardless of market size. A large clinical need does not automatically translate into a reimbursable opportunity.
Market models that ignore access realities often produce forecasts that cannot withstand scrutiny.
4. How Fast Can Behavior Actually Change?
Healthcare systems move deliberately.
Workflow integration, physician training, committee approvals, capital budgeting cycles, and institutional risk tolerance all influence adoption speed. Even clinically superior technologies scale at the pace of behavior change—not the pace of spreadsheet projections.
Ignoring this friction leads to revenue curves that rarely materialize as planned.
Why This Matters
When TAM is treated as opportunity, strategies are built around:
- Inflated top-line projections
- Overextended sales hiring
- Premature manufacturing scale
- Investor fatigue when traction lags
Conversely, when teams isolate reachable revenue first, two things happen:
- Forecasts become more credible
- Investors engage more deeply because assumptions reflect operational reality
The strongest medtech companies do not chase the largest number. They identify the most accessible segment, win there, and expand deliberately.
Focus Builds Companies
TAM has value. It defines the theoretical ceiling of a market. But it should not define your commercial strategy.
Focused markets—rooted in procedure concentration, early adopter alignment, reimbursement clarity, and realistic behavior change—are what build durable companies.
At MedTechGrowth, we encourage founders and operators to move beyond headline market size and toward constrained, executable opportunity.
The question is not “How big is the market?”
It is “How much of it can we realistically reach—and how fast?”
If you are re-evaluating your market sizing approach, we would welcome the conversation.